Orion Portfolio Solutions LLC Grows Stake in Novo Nordisk A/S (NYSE:NVO)

Orion Portfolio Solutions LLC grew its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 10.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 297,996 shares of the company's stock after buying an additional 28,331 shares during the quarter. Orion Portfolio Solutions LLC's holdings in Novo Nordisk A/S were worth $25,634,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Center for Financial Planning Inc. raised its stake in shares of Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after acquiring an additional 123 shares during the last quarter. Daiwa Securities Group Inc. bought a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth approximately $28,000. Albion Financial Group UT raised its holdings in shares of Novo Nordisk A/S by 121.4% during the fourth quarter. Albion Financial Group UT now owns 507 shares of the company's stock valued at $44,000 after acquiring an additional 278 shares in the last quarter. Sound Income Strategies LLC lifted its stake in Novo Nordisk A/S by 82.1% in the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company's stock worth $46,000 after acquiring an additional 243 shares during the period. Finally, Hager Investment Management Services LLC bought a new stake in Novo Nordisk A/S in the fourth quarter valued at $46,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Up 0.8 %

NVO stock traded up $0.56 during trading on Monday, hitting $68.76. 3,354,433 shares of the stock traded hands, compared to its average volume of 8,369,547. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The stock has a market cap of $308.54 billion, a price-to-earnings ratio of 20.91, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42. Novo Nordisk A/S has a 1 year low of $66.88 and a 1 year high of $148.15. The firm's 50 day moving average is $82.33 and its two-hundred day moving average is $98.64.

Remove Ads

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.7874 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a yield of 1.2%. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. Novo Nordisk A/S's dividend payout ratio is currently 47.72%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on NVO shares. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They set an "equal weight" rating on the stock. BNP Paribas raised Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, December 2nd. StockNews.com lowered Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research report on Friday, March 21st. Sanford C. Bernstein upgraded Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. Finally, Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Novo Nordisk A/S currently has an average rating of "Moderate Buy" and an average target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.